TORONTO, ONTARIO--(Marketwired - March 29, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming conferences.
| Investor Conference: | |
| 16 th Annual Needham Healthcare Conference | |
| Presenter: Niclas Stiernholm, Ph.D., President & Chief Executive Officer | |
| Date and Time: April 5, 2017 at 4:40 p.m. ET | |
| Location: The Westin NY Grand Central Hotel, New York | |
| Scientific Conferences: | |
| 110 th American Association for Cancer Research Annual Meeting 2017 | |
| Presenter: Gloria Lin, Ph.D., Trillium Research Scientist | |
| Title: Intratumoral Delivery of TTI-621 (SIRPaFc), a CD47-Blocking Immunotherapeutic, Inhibits Tumor Growth and Prolongs Animal Survival in a Subcutaneous B cell Lymphoma Model | |
| Date and Time: April 3, 2017, 1:00 p.m. - 5:00 p.m. ET | |
| Location: Walter E. Washington Convention Center, Washington, D.C., Halls A-C, Poster Section 26 | |
| Presenter: Emma Linderoth, Ph.D., Trillium Research Scientist | |
| Title: The Anti-Myeloma Activity of TTI-621 (SIRPαFc), a CD47-Blocking Immunotherapeutic, is Enhanced When Combined with a Proteasome Inhibitor | |
| Date and Time: April 3, 2017, 1:00 p.m. - 5:00 p.m. ET | |
| Location: Walter E. Washington Convention Center, Washington, D.C., Halls A-C, Poster Section 26 | |
About Trillium Therapeutics
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial ( NCT02663518 ) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors ( NCT02890368 ). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.
For more information visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking Information
This press release may contain forward-looking statements, which reflect Trillium's current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
